COVID-19 Cancels Charity Galas and Walks. Science Is Paying the Price

Foundations that fund biomedical research in the United States, the United Kingdom, and elsewhere are reporting record revenue drops because of the pandemic. One major factor: It has forced them to cancel key fundraising events, including glitzy galas, sponsored walks, Broadway partnerships, and more.
[ScienceInsider]
Press Release
Bookmark

No account yet? Register

Share

Virtual Lab Tours for Recruitment and Outreach

Virtual lab tours are not new, but they have never been as common as in-person lab tours. However, the pandemic has generated strong incentives for formerly in-person lab tours to go online.
[The Scientist]
Press Release
Bookmark

No account yet? Register

Share

Trump to Suspend New Visas for Foreign Scholars

With a proclamation issued on Monday, US President Donald Trump extended and expanded immigration restrictions to limit the entry of foreign workers to the United States. The move set off ripples of alarm among scientists and drew fire from experts concerned about the future of US science.
[Nature News]
Press Release
Bookmark

No account yet? Register

Share

Multiple Low Dose Therapy as an Effective Strategy to Treat EGFR Inhibitor-Resistant NSCLC Tumors

The authors showed that as little as 20% of the individual effective drug doses was sufficient to completely block MAPK signaling and proliferation when used in 3D or 4D inhibitor combinations.
[Nature Communications]
Fernandes Neto, J. M., Nadal, E., Bosdriesz, E., Ooft, S. N., Farre, L., McLean, C., Klarenbeek, S., Jurgens, A., Hagen, H., Wang, L., Felip, E., Martinez-Marti, A., Vidal, A., Voest, E., Wessels, L. F. A., van Tellingen, O., Villanueva, A., & Bernards, R. (2020). Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours. Nature Communications, 11(1), 3157. https://doi.org/10.1038/s41467-020-16952-9 Cite
Full Article
Bookmark

No account yet? Register

Share

NMPA Accepts Bio-Thera Solutions’ Biologics License Application (BLA) for BAT1706, A Proposed Biosimilar to Avastin®

Bio-Thera Solutions announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application for BAT1706, a proposed biosimilar to Avastin®.
[Bio-Thera Solutions (Business Wire, Inc.)]
Press Release
Bookmark

No account yet? Register

Share

YBX1 Mediates Autophagy by Targeting p110β and Decreasing the Sensitivity to Cisplatin in NSCLC

Scientists analyzed the expression and clinical significance of Y-box binding protein 1 and markers of autophagy in NSCLC and examined their roles in regulating sensitivity to cisplatin in NSCLC.
[Cell Death & Disease]
Full Article
Bookmark

No account yet? Register

Share

Targeting Lung Cancer Stem Cells Using Combination of Tel and Docetaxel Liposomes in 3D Cultures and Tumor Xenografts

Scientists demonstrated for the first time the efficacy of Docetaxel liposomes in combination with telmisartan in 3D cultures of H460 cells by using polysaccharide-based hydrogels and also in xenograft model of Docetaxel resistant H460 derived CD133+ lung tumors.
[Toxicology and Applied Pharmacology]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

Creatv Announces Ability to Predict Immunotherapy Treatment Response for Non-Small Cell Lung Cancer Using a Simple Blood Test

Creatv Microtech has pioneered a blood test to predict treatment response in patients with stage II-III NSCLC treated with chemoradiation therapy and consolidated immunotherapy.
[Business Wire, Inc.]
Press Release
Bookmark

No account yet? Register

Share

miR-410 Induces Both Epithelial-Mesenchymal Transition and Radioresistance through Activation of the PI3K/mTOR Pathway in Non-Small Cell Lung Cancer

Scientists demonstrated that PTEN was a direct target of miR-410 by using bioinformatic tools and dual-luciferase reporter assays, and the miR-410-induced epithelial–mesenchymal transition and radioresistance were reversed by PI3K, Akt, and mTOR inhibitors or by restoring the expression of PTEN in non-small cell lung cancer cells.
[Signal Transduction and Targeted Therapy]
Full Article
Bookmark

No account yet? Register

Share

Antisense Oligonucleotide-Mediated Correction of CFTR Splicing Improves Chloride Secretion in Cystic Fibrosis Patient-Derived Bronchial Epithelial Cells

Researchers tested an antisense oligonucleotide targeting the cystic fibrosis (CF) transmembrane conductance regulator c.3718-2477C>T mutation and showed that it effectively blocks aberrant splicing in primary bronchial epithelial cells from CF patients with the mutation.
[Nucleic Acids Research]

Sorry, but the selected Zotpress account can't be found.

Full Article
Bookmark

No account yet? Register

Share

High-Capacity Poly(2-oxazoline) Formulation of TLR 7/8 Agonist Extends Survival in a Chemo-Insensitive, Metastatic Model of Lung Adenocarcinoma

Researchers showed that their unique poly(2-oxazoline)–based nanomicellar formulation of Resiquimod, an imidazoquinoline Toll-like receptor 7/8 agonist, had a superior tumor inhibitory effect in a metastatic model of lung adenocarcinoma, relative to anti–PD-1 therapy or platinum-based chemotherapy.
[Science Advances]
Full Article
Bookmark

No account yet? Register

Share
Share